SLNO Q4 2025 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$92M

Gross Profit

$91M99.1% margin

Operating Income

$40M44.1% margin

Net Income

$43M47.3% margin

EPS (Diluted)

$0.80

QoQ Revenue Growth

+38.9%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$49M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$564M

Total Liabilities

$114M

Stockholders' Equity

$450M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92M	$0	—
Gross Profit	$91M	$0	—
Operating Income	$40M	-$59M	+168.4%
Net Income	$43M	-$56M	+177.4%